ATE281171T1 - Pharmazeutische zusammensetzung zur immunstimulierenden therapie - Google Patents
Pharmazeutische zusammensetzung zur immunstimulierenden therapieInfo
- Publication number
- ATE281171T1 ATE281171T1 AT94925945T AT94925945T ATE281171T1 AT E281171 T1 ATE281171 T1 AT E281171T1 AT 94925945 T AT94925945 T AT 94925945T AT 94925945 T AT94925945 T AT 94925945T AT E281171 T1 ATE281171 T1 AT E281171T1
- Authority
- AT
- Austria
- Prior art keywords
- immuno
- pharmaceutical composition
- stimulating therapy
- therapy
- stimulating
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 230000003308 immunostimulating effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001713 cholinergic effect Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000002766 immunoenhancing effect Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/111,288 US5449522A (en) | 1993-08-24 | 1993-08-24 | Pharmaceutical composition for immunoenhancement therapy |
| PCT/US1994/009352 WO1995005833A1 (en) | 1993-08-24 | 1994-08-15 | Pharmaceutical composition for immunoenhancement therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE281171T1 true ATE281171T1 (de) | 2004-11-15 |
Family
ID=22337628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94925945T ATE281171T1 (de) | 1993-08-24 | 1994-08-15 | Pharmazeutische zusammensetzung zur immunstimulierenden therapie |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5449522A (de) |
| EP (1) | EP0722324B1 (de) |
| JP (1) | JP3884474B2 (de) |
| AT (1) | ATE281171T1 (de) |
| AU (1) | AU689798B2 (de) |
| CA (1) | CA2170255C (de) |
| DE (1) | DE69434121T2 (de) |
| WO (1) | WO1995005833A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840770A (en) * | 1993-08-24 | 1998-11-24 | Hill Medical Corporation | Method of killing tumor cells |
| AUPM959994A0 (en) * | 1994-11-22 | 1994-12-15 | Ici Australia Operations Proprietary Limited | Water treatment process |
| US5804403A (en) * | 1997-01-31 | 1998-09-08 | Boehringer Mannheim Corporation | Stable aqueous reagent containing NAD |
| US5998386A (en) * | 1997-09-19 | 1999-12-07 | Feldman; Arthur M. | Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue |
| US6742183B1 (en) | 1998-05-15 | 2004-05-25 | United Video Properties, Inc. | Systems and methods for advertising television networks, channels, and programs |
| WO2001035943A2 (en) * | 1999-11-15 | 2001-05-25 | Gangal Hanamaraddi T | Dextrose and insulin fluid formulation for intravenous infusion |
| EP2257061A1 (de) | 2000-02-01 | 2010-12-01 | United Video Properties, Inc. | Methoden und Systeme zum erzwingen von Reklame |
| BR0207297A (pt) * | 2001-02-15 | 2005-04-19 | King Pharmaceuticals Inc | Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo |
| US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
| US20030032675A1 (en) * | 2001-02-15 | 2003-02-13 | Franz G. Andrew | Manufacture of thyroid hormone tablets having consistent active moiety amounts |
| US20030198671A1 (en) * | 2001-08-10 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique plasma AUC properties |
| US20030198667A1 (en) * | 2001-08-10 | 2003-10-23 | Franz Andrew G. | Methods of producing dispersible pharmaceutical compositions |
| US20030180353A1 (en) * | 2001-08-10 | 2003-09-25 | Franz G. Andrew | Stabilized pharmaceutical compositions |
| US20030190349A1 (en) * | 2001-08-10 | 2003-10-09 | Franz G. Andrew | Methods of stabilizing pharmaceutical compositions |
| US20030195253A1 (en) * | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration |
| US20030198672A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique triidothyronine plasma AUC properties |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| US20030203967A1 (en) * | 2001-08-14 | 2003-10-30 | Franz G. Andrew | Levothyroxine compositions having unique Tmax properties |
| US20030171436A1 (en) * | 2001-10-29 | 2003-09-11 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Tmax properties |
| AUPR987802A0 (en) | 2002-01-08 | 2002-01-31 | Commonwealth Scientific And Industrial Research Organisation | Complexing resins and method for preparation thereof |
| AU2003901583A0 (en) | 2003-04-04 | 2003-05-01 | Orica Australia Pty Ltd | A process |
| US7291272B2 (en) * | 2004-05-07 | 2007-11-06 | Orica Australia Pty Ltd. | Inorganic contaminant removal from water |
| EP1776190B1 (de) | 2004-07-28 | 2017-08-23 | IXOM Operations Pty Ltd | Pfropfenströmungsregenerationsverfahren |
| US8949901B2 (en) | 2011-06-29 | 2015-02-03 | Rovi Guides, Inc. | Methods and systems for customizing viewing environment preferences in a viewing environment control application |
| WO2013177005A1 (en) * | 2012-05-21 | 2013-11-28 | Albert Fay Hill | Metabolic syndrome and chronic disease treatments |
| WO2014164730A2 (en) | 2013-03-12 | 2014-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of cellular dna repair activity to intercept malignancy |
| CN108601827A (zh) * | 2016-02-02 | 2018-09-28 | 日东电工株式会社 | 免疫诱导促进用组合物和疫苗药物组合物 |
| US12539314B1 (en) | 2019-03-07 | 2026-02-03 | Genus Lifesciences Inc. | Aqueous oral compositions including potassium chloride |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2554453A1 (de) * | 1974-12-18 | 1976-06-24 | Experimentales Et Cliniques De | Medikament zur glykaemieregulierung |
| DE2532183C3 (de) * | 1975-07-18 | 1982-03-04 | Behringwerke Ag, 3550 Marburg | Polyionische isotonische Salzlösung zur Konservierung von Erythrozyten oder zur Perfusion und zur Konservierung von zur Transplantion bestimmter Organen |
| US4196196A (en) * | 1978-06-19 | 1980-04-01 | Tiholiz Ivan C | Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states |
| US5033998A (en) * | 1984-01-20 | 1991-07-23 | Eliot Corday | Retrograde delivery of pharmacologic and diagnostic agents via venous circulation |
| CA1299102C (en) * | 1987-06-15 | 1992-04-21 | Steven G. Ayre | Insulin potentiation therapy |
| SU1747071A1 (ru) * | 1988-08-16 | 1992-07-15 | Киевский Медицинский Институт Им.Акад.А.А.Богомольца | Способ лечени острого инфаркта миокарда |
| US5077284A (en) * | 1988-12-30 | 1991-12-31 | Loria Roger M | Use of dehydroepiandrosterone to improve immune response |
| SU1734772A1 (ru) * | 1989-10-06 | 1992-05-23 | Казахский научно-исследовательский институт клинической и экспериментальной хирургии им.А.Н.Сызганова | Способ проведени общего обезболивани при операци х в услови х гипотермии |
| HUT67319A (en) * | 1991-08-30 | 1995-03-28 | Life Medical Sciences Inc | Compositions for treating wounds |
-
1993
- 1993-08-24 US US08/111,288 patent/US5449522A/en not_active Expired - Lifetime
-
1994
- 1994-08-15 AT AT94925945T patent/ATE281171T1/de not_active IP Right Cessation
- 1994-08-15 JP JP50767095A patent/JP3884474B2/ja not_active Expired - Lifetime
- 1994-08-15 DE DE69434121T patent/DE69434121T2/de not_active Expired - Lifetime
- 1994-08-15 AU AU75697/94A patent/AU689798B2/en not_active Expired
- 1994-08-15 CA CA002170255A patent/CA2170255C/en not_active Expired - Lifetime
- 1994-08-15 EP EP94925945A patent/EP0722324B1/de not_active Expired - Lifetime
- 1994-08-15 WO PCT/US1994/009352 patent/WO1995005833A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2170255A1 (en) | 1995-03-02 |
| AU689798B2 (en) | 1998-04-09 |
| CA2170255C (en) | 2000-05-16 |
| EP0722324A4 (de) | 1999-06-16 |
| EP0722324B1 (de) | 2004-11-03 |
| DE69434121T2 (de) | 2005-10-27 |
| AU7569794A (en) | 1995-03-21 |
| DE69434121D1 (de) | 2004-12-09 |
| US5449522A (en) | 1995-09-12 |
| JPH09509136A (ja) | 1997-09-16 |
| WO1995005833A1 (en) | 1995-03-02 |
| JP3884474B2 (ja) | 2007-02-21 |
| EP0722324A1 (de) | 1996-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE281171T1 (de) | Pharmazeutische zusammensetzung zur immunstimulierenden therapie | |
| DK1033981T3 (da) | Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet | |
| PT1035834E (pt) | Forma de dosagem osmotica que compreende primeiro e segundo revestimentos | |
| WO1994027589A3 (en) | Antidepressant dosage form | |
| EP0693924A4 (de) | Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen | |
| ES2062392T3 (es) | Medicamentos que comprenden salmeterol y fluticasona. | |
| NZ217483A (en) | Composition for delivery of hydrophobic drugs | |
| SE8504945L (sv) | Farmaceutiska kompositioner innehallande antracyklinglykosider | |
| DK1126828T3 (da) | Oral indgivelse af adenosin-analoger | |
| DE69531098D1 (de) | Piperidine und pyrrolidine | |
| AU4258101A (en) | Combination therapies with vascular damaging activity | |
| EP0934065A4 (de) | Pharmazeutische zusammensetzung | |
| NO994165L (no) | Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet | |
| UA32457C2 (uk) | Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм | |
| NO943288L (no) | Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer | |
| PL315127A1 (en) | Deuterised biologically active substances for percutaneous administration | |
| AU8687391A (en) | Lithium treatment | |
| HRP20000781B1 (hr) | Šumeći pripravci | |
| DE59510583D1 (de) | Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid | |
| EP0384302A3 (de) | Verwendung von Ubenimex zur Hestellung eines Medikaments zur Behandlung des myelodysplastischen Syndroms | |
| ATE313323T1 (de) | Pharmazeutische zubereitungen | |
| ES2161809T3 (es) | Uso de factor proliferativo osteoblastico. | |
| AR013498A1 (es) | Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa | |
| SE9803623D0 (sv) | New therapeutic application | |
| IL110888A (en) | Pharmaceutical compositions for the treatment of liver diseases comprising a vasodilating compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |